

صفاء أبو السعود محمد



شبكة المعلومات الجامعية

# بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ




صفاء أبو السعود محمد



شبكة المعلومات الجامعية



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



صفاء أبو السعود محمد



شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الإلكتروني والميكرو فيلم


## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



صفاء أبو السعود محمد



شبكة المعلومات الجامعية



# بعض الوثائق الأصلية تالفة



صفاء أبو السعود محمد



شبكة المعلومات الجامعية



# بالرسالة صفحات لم ترد بالأصل



**Studying The Effects Of Carvedilol And  
Atenolol In Pediatric Patients With  
Chronic Heart Failure**

*A Dissertation Presented*

*By*

**HOSNY AHMED ELEWA**

Pharm.D.

For The Fulfillment For The  
Doctor of Philosophy Degree

*In*

Pharmaceutical Sciences  
(*Clinical Pharmacy*)

*Supervisors*

*Dr.*

**OSAMA M. H. IBRAHIM**

Associate Professor of Clinical Pharmacy  
Faculty of Pharmacy  
Tanta University

*Prof. Dr.*


**MOSTAFA EL SAYED ABO FARRAG**

Professor of Pediatrics  
Faculty of Medicine  
Tanta University.

**CLINICAL PHARMACY DEPARTMENT  
FACULTY OF PHARMACY  
TANTA UNIVERSITY**

2005


B13280




"قَالُوا سُبْحَانَكَ لَا عِلْمَ  
لَنَا إِلَّا مَا عَلَّمْتَنَا  
إِنَّكَ أَنْتَ الْعَلِيمُ  
الْحَكِيمُ"

صدق الله العظيم


البقرة - 32



قرآن كريم

A faint, stylized illustration of a rainbow arching over a waterfall. The rainbow is composed of many thin, parallel lines, and the waterfall is depicted as a series of vertical lines falling from the center of the rainbow's arch.

**F**irst, and for most thanks to  
**ALLAH**, the most merciful,  
gracious and compassionate,  
to **ALLAH** everything in life  
is resumed.



## ACKNOWLEDGEMENTS

*First of all and above all great thanks to  
ALLAH whose blessings on me can not be  
counted.*

*The sincerest thanks, deepest appreciation and  
greatest admiration to Dr. Osama Mohamed Ibrahim,  
Associate Professor of the Clinical Pharmacy, Clinical  
Pharmacy Department, Faculty of Pharmacy, Tanta  
University, for his encouragement, continuous support to  
complete this work, valuable instructions and suggestions  
throughout the work, and the tremendous effort he has  
done in the meticulous revision of the entire dissertation. I  
feel greatly honored to work under his supervision.*

*My deepest appreciation and grateful thanks are due  
to Prof. Dr. Mostafa El Sayed Abo Farrag, Professor of  
Pediatrics, Pediatrics Department, Faculty of Medicine,  
Tanta University for his generous effort, valuable  
observations, patience, kind assistance, valuable advises,  
kindness and constructive criticism.*

*In addition my heartfelt thanks to all staff members  
of the Pediatric Department for helping me in the  
collections of patients enrolled in this work.*

*My thanks are also due to all the staff members of the  
Clinical Pharmacy Department, Tanta University, for  
their kind support and cooperation.*

# APPROVAL SHEET

Approval Committee:

Signature

***Prof. Dr. Osama Abed Rab El Rassol***  
Professor of Pediatrics, Faculty of Medicine,  
Tanta University.




***Prof. Dr. Hassan Mahmoud El Fayomy***  
Professor of Pharmacology, Faculty of Pharmacy,  
Zagazek University.




***Prof. Dr. Mostafa El Sayed Abo Farrag***  
Professor of Pediatrics, Faculty of Medicine,  
Tanta University.



***Dr. Osama M. H. Ibrahim***  
Associate Professor of Clinical Pharmacy,  
Faculty of Pharmacy, Tanta University.



Date: November,7 ,2005



	Page No.
GLOSSARY OF SYMBOLS-----	1
LIST OF TABLES-----	3
LIST OF FIGURES-----	6
INTRODUCTION-----	8
REVIEW OF LITERATURES-----	9
▪ Definition and pathophysiology of CHF-----	9
▪ Frank-Starling relationship-----	10
▪ Adverse effects of adrenergic stimulation-----	11
▪ Consequences of alteration in signal transduction on myocardial function-----	12
▪ Apoptosis-----	12
▪ Autonomic nervous system-----	13
▪ Renin angiotensin system (RAS)-----	14
▪ Arginine vasopressin-----	15

	Page No.
▪ Cytokines -----	16
▪ Myocardial energy metabolism in HF-----	17
▪ Neuro-hormonal pathways -----	20
▪ Causes of heart failure-----	22
▪ Clinical manifestations of CHF-----	26
▪ Clinical manifestations of CHF in new-born-----	28
▪ Laboratory studies-----	30
▪ Management of CHF-----	31
A) General measures for management of CHF -----	32
B) Digitals-----	34
C) Diuretics-----	51
D) Angiotensin converting enzyme inhibitors-----	57
E) Beta blockers-----	60
F) Carvedilol-----	64
<b>AIM OF THE WORK-----</b>	<b>69</b>

	<b>Page No.</b>
<b>SUBJECTS AND METHODS</b> -----	70
<b>RESULTS</b> -----	89
<b>DISCUSSION</b> -----	131
<b>SUMMARY AND CONCLUSIONS</b> -----	141
<b>REFERENCES</b> -----	144
<b>ARABIC SUMMARY</b> -----	161

IM	Intramuscular
iNOS	Inducible nitric oxide synthetase
ISA	Intrinsic sympathomimetic activity
IV	Intravenous
LDL	Low density lipoprotein
LV	Left ventricle
LVED	Left ventricular end diastolic pressure
LVEF	Left ventricular ejection fraction
NADH	Reduced nicotinamide adenine
NE	Nor-epinephrine
NEDD	N (1-naphthyl) ethelenediamine dihydro- Chloride
nNOS	Neuronal nitric oxide synthetase
NO	Nitric oxide
NOS	Nitric oxide system
NOS 1	Nitric oxide synthetase type 1
NOS 2	Nitric oxide synthetase type 2
NOS 3	Nitric oxide synthetase type 3
NSAID	Non steriodal anti-inflammatory drugs
NYHA	New York Heart Association
oz	Ounce
PDA	Patent ductus arteriosus
PDH	Pyruvate dehydrogenase
pg	Pico gram
PGS	Prostaglandins
Pi	Inorganic phosphate
PKA	Protein kinase
PVR	Peripheral vascular resistance
RAAS	Renin angiotensin aldosterone system
RAS	Renin angiotensin converting enzyme
RDS	Respiratory distress syndrome
RF	Rheumatic fever
RV	Right ventricle
SOLVD	Studies On Left Ventricular Dysfunction
SULF	Sulfanilamide
TNF $\alpha$	Tumor necrosis factor alpha
V	Vasopressin
Vcl <sub>3</sub>	Vanadium (III) chloride.
VSD	Ventricular septal defect

# LIST OF TABLES

3

Table No.		Page
1	Features of HF in infants-----	29
2	Comparisons of the systemic availability and equivalent doses for preparations of digoxin-----	35
3	Dosage recommendations for digoxin-----	39
4	Signs and symptoms of digitalis toxicity-----	41
5	Electrolyte abnormalities and cardiac glycosides toxicity-----	42
6	Management of digitalis toxicity-----	46
7	Diuretic dosages-----	56
8	The three adrenergic receptors in human cardiac myocytes-----	63
9	Baseline characteristics of patients in the three groups-----	73
10	Grouping of patients of the present study according to NYHA functional classification-----	74
11	Standard concentrations of nitrite (stable metabolite of NO) ---	77
12	Serum levels of nitric oxide in carvedilol-treated patients using Griess reagent-----	90
13	Serum levels of nitric oxide in atenolol-treated patients using Griess reagent-----	91
14	Serum levels of nitric oxide in conventional group using Griess reagent-----	92
15	Mean serum levels of nitric oxide (NO) production ( $\mu\text{mol/L}$ ) in the three groups-----	93